Allstate
ALL
$256.45
+1.92%
The Allstate Corporation is one of the largest US property-casualty insurers, primarily offering personal auto and homeowners insurance through a network of about 6,000 exclusive agents. As a market leader in the P&C insurance space, Allstate distinguishes itself through its strong brand, extensive agency force, and disciplined underwriting. The current investor narrative centers on the company's exceptional earnings momentum driven by significantly lower catastrophe losses in 2026, which is expected to power a strong Q2, alongside benefits from a high-interest-rate environment that boosts investment yields and margins.…
ALL
Allstate
$256.45
Related headlines
Investment Opinion: Should I buy ALL Today?
Rating: Buy. The thesis is that Allstate's deeply discounted valuation (trailing P/E 5.4x) and strong free cash flow ($9.88B TTM) provide a margin of safety, while the potential for sustained underwriting profitability and investment income from high interest rates offers upside. Analyst consensus is bullish with Outperform/Overweight ratings from multiple firms, and the average EPS estimate of $25.47 implies a forward P/E of 9.9x, suggesting modest upside.
Supporting evidence: Trailing P/E of 5.4x is a deep discount to the industry average of 15-20x. Revenue growth is modest at 1.5% YoY, but net income surged 98% YoY in Q4 2025. ROE of 33.6% is exceptional, and free cash flow yield (FCF/price) is approximately 3.9% based on market cap of $54.4B. The PEG ratio of 0.04 suggests the stock is cheap relative to its earnings growth, though this metric should be used cautiously due to cyclicality.
Risks & Conditions: The biggest risks are earnings normalization (forward P/E implies a decline) and catastrophe losses. If trailing P/E expands above 10x (i.e., price above $467 based on TTM EPS of ~$46.76), the stock would no longer be a deep value, and the rating would shift to Hold. If revenue growth decelerates below 0% or net margin falls below 10%, a Sell rating would be warranted. Overall, the stock appears undervalued relative to its history and peers, but the valuation discount reflects the market's skepticism about earnings sustainability.
Sign up to view all
ALL 12-Month Price Forecast
Allstate's deep value valuation and strong cash flow generation make it an attractive investment, but the market's skepticism about earnings sustainability limits upside. The base case of moderate earnings normalization is most likely, but the bull case of sustained profitability could drive significant re-rating. The key factor to watch is catastrophe loss trends; if they remain low, the stock could outperform. The stance is bullish with medium confidence due to the uncertainty around earnings normalization. An upgrade to high confidence would require evidence of sustained underwriting margins above 15%, while a downgrade to neutral would follow a major catastrophe event.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Allstate's 12-month outlook, with a consensus price target around $333.38 and implied upside of +30.0% versus the current price.
Average Target
$333.38
5 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
5
covering this stock
Price Range
$205 - $333
Analyst target range
Allstate is covered by 5 analysts, with a consensus leaning bullish. Ratings include Outperform from Mizuho and Keefe, Bruyette & Woods, Overweight from JP Morgan, and Equal Weight/Neutral from Wells Fargo, Citigroup, and Cantor Fitzgerald. The average EPS estimate for the next fiscal year is $25.47, with a range of $23.24 to $27.60. The average revenue estimate is $66.30 billion, with a range of $65.11B to $67.15B. While specific price targets are not provided, the consensus EPS estimate implies a forward P/E of 9.9x at the current price, suggesting modest upside if the multiple expands. The spread between the low and high EPS estimates ($23.24 to $27.60) indicates moderate uncertainty about earnings sustainability. Recent ratings actions have been stable, with no downgrades or upgrades in the past six months, suggesting analysts are comfortable with the current outlook. The lack of a wide dispersion in ratings (no strong sell or buy outliers) points to a relatively high conviction in the stock's near-term prospects.
Drowning in data?
Find the real signal!
Bulls vs Bears: ALL Investment Factors
Allstate presents a compelling value case with a trailing P/E of 5.4x, strong free cash flow of $9.88B, and a defensive beta of 0.166. However, the market is pricing in a significant earnings decline, as evidenced by the forward P/E of 9.5x versus trailing. The bull case rests on the sustainability of improved underwriting and investment income from high interest rates, while the bear case warns of earnings normalization and catastrophe risk. Currently, the evidence slightly favors the bull case given the deep valuation discount and strong balance sheet, but the key tension is whether the exceptional Q4 2025 net margin of 23.1% is sustainable or reverts to historical levels. If earnings hold up, the stock could re-rate higher; if they decline, the stock may remain range-bound.
Bullish
- Exceptional earnings momentum: Net income surged to $3.83B in Q4 2025 (net margin 23.1%) from $1.93B a year earlier (net margin 11.8%), driven by lower catastrophe losses and improved underwriting. This dramatic improvement highlights the company's operating leverage.
- Deeply discounted valuation: Trailing P/E of 5.4x and forward P/E of 9.5x are well below the typical P&C insurance industry average of 15-20x. Even the forward multiple implies significant undervaluation if earnings normalize at a higher level than historically.
- Strong balance sheet and cash flow: Debt-to-equity of 0.24 and interest coverage of 50.2x indicate low financial risk. Free cash flow TTM of $9.88B provides ample liquidity for dividends (yield 2.12%) and share buybacks.
- Defensive characteristics with low beta: Beta of 0.166 means the stock is significantly less volatile than the market, making it a defensive holding. This is attractive for risk-averse investors, especially in uncertain macro environments.
Bearish
- Earnings normalization risk: Forward P/E of 9.5x implies the market expects earnings to decline from current elevated levels. The trailing P/E of 5.4x suggests current earnings are unsustainably high, likely due to abnormally low catastrophe losses.
- Near 52-week high with limited upside: Stock at $251.61 is 97.6% of its 52-week range and only 2.4% below the 52-week high of $257.67. This limits near-term upside potential and increases risk of a pullback.
- Revenue growth is modest: Q4 2025 revenue of $16.59B grew only 1.5% YoY. While consistent, this low single-digit growth does not justify a growth stock premium and makes the stock reliant on margin expansion for earnings growth.
- Skepticism from analyst estimates: Average EPS estimate of $25.47 for next fiscal year implies a decline from the TTM EPS of ~$46.76 (trailing P/E 5.4x). The wide range ($23.24 to $27.60) indicates uncertainty about earnings sustainability.
ALL Technical Analysis
Allstate is in a sustained uptrend, with the stock up 29.2% over the past year, significantly outperforming the S&P 500's 20.6% gain. The current price of $251.61 sits at 97.6% of its 52-week range (low $188.08, high $257.67), indicating strong momentum and positioning near the upper end of its yearly band. This near-high positioning suggests bullish sentiment but also carries risk of overextension, as the stock is only 2.4% below its 52-week high. Short-term momentum is accelerating sharply, with a 1-month gain of 12.7% and a 3-month gain of 19.3%, both outpacing the S&P 500's respective returns of 4.1% and 11.1%. The 1-month relative strength of 8.6% versus the market confirms strong near-term outperformance. This acceleration aligns with the longer-term uptrend, reinforcing a bullish outlook without signs of divergence. Key support lies at the 52-week low of $188.08, while resistance is at the 52-week high of $257.67. A breakout above $257.67 would signal continuation of the uptrend, potentially opening room for further gains. The stock's beta of 0.166 indicates significantly lower volatility than the market, meaning Allstate is a defensive holding that tends to decline less in downturns—important for risk-conscious investors.
Beta
0.17
0.17x market volatility
Max Drawdown
-11.5%
Largest decline past year
52-Week Range
$188-$258
Price range past year
Annual Return
+32.6%
Cumulative gain past year
| Period | ALL Return | S&P 500 |
|---|---|---|
| 1m | +15.7% | +1.0% |
| 3m | +19.3% | +7.9% |
| 6m | +30.8% | +8.5% |
| 1y | +32.6% | +20.1% |
| ytd | +25.8% | +9.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ALL Fundamental Analysis
Revenue has been steadily growing, with the most recent quarter (Q4 2025) reporting $16.59 billion, up 1.5% year-over-year. Over the trailing four quarters, revenue has ranged from $16.26B to $17.06B, showing consistent top-line expansion driven by policy growth in personal auto and homeowners lines. The Property Liability segment generated $29.69 billion in revenue, while Protection Services contributed $1.83 billion, highlighting the core insurance business as the primary growth driver. Profitability has improved dramatically, with net income surging to $3.83 billion in Q4 2025 (net margin 23.1%) from $1.93 billion a year earlier (net margin 11.8%). Gross margin expanded to 53.0% in Q4 2025 from 30.1% in Q4 2024, reflecting lower catastrophe losses and improved underwriting. Operating margin reached 29.6% in Q4 2025, up from 15.0% in the prior-year quarter, indicating strong operational leverage. The balance sheet is solid, with a debt-to-equity ratio of 0.24 and interest coverage of 50.2x, indicating low financial risk. Free cash flow was $2.9 billion in Q4 2025, and trailing twelve-month free cash flow reached $9.88 billion, providing ample liquidity for dividends and share buybacks. ROE stands at 33.6%, well above the industry average, reflecting efficient capital use.
Quarterly Revenue
$16.6B
2025-12
Revenue YoY Growth
+1.5%
YoY Comparison
Gross Margin
53.0%
Latest Quarter
Free Cash Flow
$9.9B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ALL Overvalued?
Since net income is positive, the primary valuation metric is the P/E ratio. The trailing P/E is 5.4x, while the forward P/E is 9.5x, implying the market expects earnings to decline from current elevated levels. The gap between trailing and forward P/E suggests that the market is pricing in a normalization of earnings after a period of exceptionally low catastrophe losses. Compared to the industry average P/E (not provided, but typically around 15-20x for P&C insurers), Allstate's trailing P/E of 5.4x appears deeply discounted. However, the forward P/E of 9.5x still represents a significant discount to the sector, likely reflecting skepticism about the sustainability of current profit margins. Historically, Allstate's trailing P/E has ranged from negative (during loss years) to over 30x. The current trailing P/E of 5.4x is near the low end of its historical range, which could indicate a value opportunity if earnings remain strong, or a value trap if earnings revert to mean. The PEG ratio of 0.04 suggests the stock is cheap relative to its earnings growth rate, but this metric should be interpreted cautiously given the cyclical nature of insurance earnings.
PE
5.4x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -1458x~32x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
4.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Allstate's earnings are highly cyclical, driven by catastrophe losses and underwriting results. The Q4 2025 net margin of 23.1% is exceptional and may not be sustainable; a return to more normal loss levels could compress margins significantly. The company carries $98M in quarterly interest expense, but with interest coverage of 50.2x, debt is manageable. However, the low revenue growth of 1.5% YoY means earnings growth is heavily dependent on margin expansion, which is vulnerable to adverse events. Free cash flow of $9.88B TTM is strong, but if catastrophe losses spike, cash flow could deteriorate rapidly.
Market & Competitive Risks: The stock trades near its 52-week high, leaving limited upside and increasing the risk of a pullback. With a beta of 0.166, Allstate is defensive but may underperform in strong bull markets. Competitive pressures from other large insurers like Progressive and Geico could pressure pricing and market share. Regulatory changes in insurance pricing or capital requirements could also impact profitability. The high interest rate environment benefits investment income, but if rates decline, that tailwind could reverse.
Worst-Case Scenario: A severe catastrophe season (e.g., multiple hurricanes or wildfires) could cause large underwriting losses, eroding net income and sending the stock down to its 52-week low of $188.08. Combined with a normalization of earnings, the stock could fall approximately 25% from the current price of $251.61. In a prolonged downturn, the stock could test even lower levels, but the strong balance sheet and low debt provide a floor.
FAQ
The primary risk is earnings normalization: the trailing P/E of 5.4x reflects exceptionally high net income (net margin 23.1% in Q4 2025), and if earnings revert to historical levels, the stock could decline. Catastrophe losses are a major risk—a severe hurricane or wildfire season could cause large underwriting losses and compress margins. Interest rate risk is also relevant: if the Fed cuts rates, investment income would decline, reducing profitability. Finally, the stock's proximity to its 52-week high (only 2.4% below) limits near-term upside and increases the risk of a pullback. The most severe risk is a combination of these factors, which could drive the stock down 25% to the 52-week low of $188.08.
The 12-month outlook is moderately bullish. The base case (50% probability) sees the stock trading between $240 and $270, with earnings normalizing moderately and the forward P/E around 10x. The bull case (30% probability) targets $270-$300, driven by sustained low catastrophe losses and multiple expansion to 12x forward earnings. The bear case (20% probability) sees the stock falling to $188-$220 if a major catastrophe or rate cuts hurt earnings. Analyst consensus is positive, with an average EPS estimate of $25.47 for next fiscal year, implying a forward P/E of 9.9x at the current price. The most likely scenario is the base case, where the stock remains range-bound near current levels.
Allstate appears undervalued based on trailing metrics, with a P/E of 5.4x versus the industry average of 15-20x. However, the forward P/E of 9.5x suggests the market is pricing in a significant earnings decline, making the stock fairly valued on a forward basis if earnings normalize. The PEG ratio of 0.04 indicates the stock is cheap relative to its recent growth, but this metric is distorted by the cyclical spike in earnings. Compared to its own history, the trailing P/E is near the low end of its range, which could indicate a value opportunity or a value trap. The market is essentially paying a low multiple for earnings that may not persist, so the valuation is only attractive if you believe current profitability is sustainable.
Allstate is a good buy for value-oriented investors with a medium-term horizon. The stock trades at a trailing P/E of 5.4x, a deep discount to the P&C insurance industry average of 15-20x, and offers a dividend yield of 2.12%. However, the forward P/E of 9.5x implies the market expects earnings to decline, so the investment thesis hinges on whether current profitability is sustainable. The strong free cash flow of $9.88B TTM and low beta of 0.166 provide a margin of safety. For investors willing to accept the risk of earnings normalization, the stock offers attractive upside potential if the market re-rates the multiple. It is less suitable for growth-focused investors seeking high revenue growth.
Allstate is better suited for long-term investment due to its defensive characteristics (beta 0.166) and dividend yield of 2.12%. The stock's low volatility makes it a good core holding for patient investors. Short-term trading is riskier given the stock is near its 52-week high and could experience pullbacks. The earnings cycle in P&C insurance can be volatile, so a minimum holding period of 3-5 years is recommended to ride out potential earnings normalization. For long-term investors, the deep valuation and strong cash flow provide a margin of safety, while short-term traders may find limited upside catalysts in the near term.
